

FH535

Catalog No: tcsc1538



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

108409-83-2

Formula:

$C_{13}H_{10}Cl_2N_2O_4S$

Pathway:

Cell Cycle/DNA Damage;Stem Cell/Wnt;Stem Cell/Wnt

Target:

PPAR; β -catenin;Wnt

Purity / Grade:

>98%

Solubility:

DMSO : 33.33 mg/mL (92.28 mM; Need ultrasonic); H2O :

Observed Molecular Weight:

361.2

Product Description


FH535 is an inhibitor of **Wnt/ β -catenin** and **PPAR**, with anti-tumor activities.

IC50 & Target: Wnt, β -catenin, PPAR^[1]

In Vitro:

FH535 is an inhibitor of Wnt/ β -catenin and PPAR. FH535 inhibits PPAR γ and PPAR δ transactivation in HCT116 cells. FH535 (15 μ M) activities depend on functional PPAR δ but does not require a cysteine residue in the PPAR ligand-binding domain. FH535 inhibits recruitment of the coactivators GRIP1 and β -catenin to PPAR δ and PPAR γ . FH535 shows toxic effects on 12 carcinoma cell lines expressing wnt/ β -catenin pathway^[1]. FH535 (20 μ M) suppresses the β -catenin pathway in pancreatic cancer cells, and inhibits pancreatic cancer cell migration. Furthermore, FH535 (20, 40 μ M) inhibits pancreatic cancer cell invasion and cell growth^[2]. FH535 represses angiogenesis-related genes in pancreatic cancer cells^[3].

In Vivo: FH535 (25 mg/kg, i.p.) exhibits an anti-tumor effect on pancreatic cancer xenografts in mice. FH535 also represses angiogenesis in pancreatic cancer xenografts^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!